PolyPid (PYPD)

Currency in USD
3.4100
+0.0500(+1.49%)
Closed·
After Hours
3.40000.0000(0.00%)
·
PYPD Scorecard
Full Analysis
Quickly burning through cash
PYPD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.31003.4666
52 wk Range
2.30003.9300
Key Statistics
Prev. Close
3.36
Open
3.37
Day's Range
3.31-3.4666
52 wk Range
2.3-3.93
Volume
22.93K
Average Volume (3m)
499.87K
1-Year Change
-6.58%
Book Value / Share
0.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PYPD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.7500
Upside
+273.90%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

PolyPid News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Sell
Technical Indicators
Sell
Moving Averages
Sell

PolyPid Company Profile

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Employees
59

PolyPid Earnings Call Summary for Q4/2024

  • Q4 2024 net loss widened to $8.5M from $6.4M in Q4 2023; full-year loss increased to $29M from $23.9M in 2023
  • R&D expenses rose to $7M in Q4 2024, up from $4.6M in Q4 2023, reflecting investment in DPLEX-100 Phase III SHIELD-II trial
  • Stock dropped 6.19% post-earnings; company faces financial stability challenges with $19.63M market cap and -48.54 Altman Z-Score
  • SHIELD-II trial enrollment to complete by March 2025; top-line results expected Q2 2025; NDA submission contingent on outcomes
  • Analysts forecast -$4.18 EPS for 2024; company exploring partnerships to enhance U.S. and global market presence
Last Updated: 12/02/2025, 15:32
Read Full Transcript

Compare PYPD to Peers and Sector

Metrics to compare
PYPD
Peers
Sector
Relationship
P/E Ratio
−1.1x−1.0x−0.5x
PEG Ratio
−0.02−0.010.00
Price/Book
404.1x1.6x2.6x
Price / LTM Sales
-1.6x3.2x
Upside (Analyst Target)
301.8%173.2%45.7%
Fair Value Upside
Unlock19.7%8.6%Unlock

Analyst Ratings

4 Buy
0 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 12.7500
(+273.90% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.70 / -0.92
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PYPD Income Statement

People Also Watch

31.68
BMNR
-8.55%
0.92
KLTO
-4.15%
168.10
CRCL
-8.40%
2.56
INMB
-6.23%
0.811
GAME
-5.48%

FAQ

What Stock Exchange Does PolyPid Trade On?

PolyPid is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for PolyPid?

The stock symbol for PolyPid is "PYPD."

What Is the PolyPid Market Cap?

As of today, PolyPid market cap is 34.75M.

What Is PolyPid's Earnings Per Share (TTM)?

The PolyPid EPS (TTM) is -4.02.

When Is the Next PolyPid Earnings Date?

PolyPid will release its next earnings report on 04 Nov 2025.

From a Technical Analysis Perspective, Is PYPD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has PolyPid Stock Split?

PolyPid has split 1 times.

How Many Employees Does PolyPid Have?

PolyPid has 59 employees.

What is the current trading status of PolyPid (PYPD)?

As of 02 Aug 2025, PolyPid (PYPD) is trading at a price of 3.41, with a previous close of 3.36. The stock has fluctuated within a day range of 3.31 to 3.47, while its 52-week range spans from 2.30 to 3.93.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.